Comparison 4. Children with candidaemia or invasive candidiasis: itraconazole versus fluconazole.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality (all cause)	1	43	Risk Ratio (M‐H, Random, 95% CI)	0.52 [0.11, 2.56]
2 Mortality (related to fungal infection)	1	43	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.07, 15.69]
3 Complete resolution of fungal infection	1	43	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.74, 1.32]
4 Partial resolution of fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Resolution of fever in suspected fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6 Progression of disease requiring change / addition of an antifungal agent	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
7 Breakthrough fungal infection requiring change / addition of an antifungal agent	1	43	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
8 Any clinically significant adverse reactions attributed to the antifungal agent resulting in discontinuation, dose reduction or change in therapy	1	43	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
9 Any clinically significant adverse reactions attributed to the antifungal agent (total)	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
10 Nephrotoxicity	1	35	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.13, 3.72]
11 Hypokalaemia	1	35	Risk Ratio (M‐H, Random, 95% CI)	1.06 [0.25, 4.54]
12 Hepatotoxicity	1	35	Risk Ratio (M‐H, Random, 95% CI)	1.06 [0.07, 15.62]
13 Infusion‐related reactions	1	43	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
14 Gastrointesintal toxicity	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
15 Neurological disturbances	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Haematological disturbances	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
17 Length of stay	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
18 Quality of life	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
19 Cost	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]